DYNE THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.76 USD | -0.38% |
|
+5.68% | +138.46% |
| 05-23 | Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing | MT |
| 05-22 | Dyne Therapeutics Prices $325.5 Million Common Stock Offering | MT |
Presenter SpeechAmy Reilly (Executives)Good morning, everyone. I'm Amy Reilly, Senior Vice Pre...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
Calendar
2024-06-06
- Jefferies Global Healthcare Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
31.88
USD
Average target price
45.9
USD
Spread / Average Target
+43.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +138.46% | 3.16B | |
| +46.13% | 54.63B | |
| -6.62% | 39.92B | |
| +37.07% | 38.82B | |
| +13.27% | 26.86B | |
| -11.17% | 26.22B | |
| -21.64% | 18.78B | |
| +25.56% | 12.21B | |
| +0.40% | 12.16B | |
| +25.74% | 11.94B |
- Stock Market
- Equities
- DYN Stock
- News Dyne Therapeutics, Inc.
- Transcript : Dyne Therapeutics, Inc. - Special Call
